Search

TG Therapeutics Inc

Закрыт

СекторЗдравоохранение

56.56 -1.51

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

57.09

Макс.

57.59

Ключевые показатели

By Trading Economics

Доход

7.8M

28M

Продажи

35M

240M

P/E

Средняя по отрасли

20.861

55.725

Прибыль на акцию

0.05

Рентабельность продаж

11.466

Сотрудники

399

EBITDA

-6.4M

22M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+20.44% upside

Дивиденды

By Acuity

Следующий отчет о доходах

2 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

1.7B

8.7B

Предыдущая цена открытия

58.07

Предыдущая цена закрытия

56.56

Новостные настроения

By Acuity

68%

32%

271 / 339 Рейтинг в Healthcare

TG Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

25 сент. 2026 г., 21:01 UTC

TG Therapeutics Inc declined in after-market trading, reversing an initial uptick and moving lower from Friday's close, despite remaining above its 20-day moving average.

24 сент. 2026 г., 23:45 UTC

TG Therapeutics Inc declined in after-market hours on Thursday, moving from a larger drop to a more modest decrease while remaining above its 20-day moving average.

23 сент. 2026 г., 23:01 UTC

TG Therapeutics Inc declined in after-market trading, reversing an initial uptick, despite strong U.S. economic data indicating robust growth in the private sector.

22 сент. 2026 г., 22:06 UTC

TG Therapeutics Inc saw a slight decline in after-market trading, despite recent strength, as economic data showed a contraction in manufacturing activity.

21 сент. 2026 г., 19:16 UTC

Social Media

TG Therapeutics shares are advancing as discussions highlight BRIUMVI's growing momentum and market share gains in the IV anti-CD20 market for relapsing multiple sclerosis.

18 сент. 2026 г., 20:06 UTC

TG Therapeutics is trading modestly higher, rebounding after an earlier pullback, and has now finished higher for three consecutive sessions.

17 сент. 2026 г., 19:54 UTC

TG Therapeutics Inc is moving higher as economic data shows unexpected labor market strength, despite a decline in housing starts.

16 сент. 2026 г., 23:56 UTC

TG Therapeutics Inc is trading lower in after-market hours, retracing from an initial high shortly after the market closed, despite remaining above its 20-day moving average.

15 сент. 2026 г., 23:41 UTC

TG Therapeutics shares are lower in after-market trading amid negative market sentiment. The New York Empire State Manufacturing Index fell sharply, raising investor caution.

14 сент. 2026 г., 19:16 UTC

Social Media

TG Therapeutics Inc shares are lower today amid broader market declines. CEO Weiss highlighted upcoming catalysts, including a significant treatment administration method.

11 сент. 2026 г., 20:08 UTC

Social Media

TG Therapeutics shares are declining during Friday's session, despite social media optimism about its subcutaneous BRIUMVI formulation and potential Priority Review Voucher benefits.

10 сент. 2026 г., 20:31 UTC

TG Therapeutics Inc shares are lower in after-market trading, reflecting a decline despite starting the session near the top of their one-month range.

9 сент. 2026 г., 20:07 UTC

Social Media

TG Therapeutics shares are lower today amid cautious outlook from CEO Weiss and mixed analyst sentiment on sales estimates. Earlier, the stock pulled back from session highs.

4 сент. 2026 г., 20:07 UTC

Social Media

TG Therapeutics Inc is declining amid increased selling pressure in risk assets following a strong jobs report raising monetary policy concerns.

3 сент. 2026 г., 20:07 UTC

News
Social Media

TG Therapeutics will participate in the Cantor Global Healthcare Conference. Shares are lower today, despite earlier gains and positive sentiment surrounding the company.

2 сент. 2026 г., 20:02 UTC

Social Media

TG Therapeutics shares are higher as HC Wainwright reiterates its Buy rating. Social media valuations suggest a price range of $78 to $85 per share.

1 сент. 2026 г., 19:54 UTC

News
Social Media

TG Therapeutics shares are rising as H.C. Wainwright maintains a Buy rating and sets a price target of $78, indicating significant upside potential.

31 авг. 2026 г., 22:16 UTC

TG Therapeutics Inc. shares showed little change in after-market trading. The stock remains above its 20-day moving average, indicating stability.

28 авг. 2026 г., 19:51 UTC

TG Therapeutics Inc shares are lower today, continuing a decline since Thursday's close. The stock remains above its 20-day moving average.

27 авг. 2026 г., 23:41 UTC

TG Therapeutics Inc shares are lower in after-market hours, reflecting broader market declines. Economic indicators have not alleviated cautious sentiment amid inflation concerns.

26 авг. 2026 г., 19:16 UTC

Social Media
News

TG Therapeutics raised its Briumvi revenue guidance to $890-$905 million, contributing to an upgrade of TGTX stock. Shares are trading roughly flat today.

25 авг. 2026 г., 23:36 UTC

TG Therapeutics Inc. shares are trading roughly flat in after-market hours. The stock remains above its 20-day moving average and near its one-month trading range.

24 авг. 2026 г., 23:21 UTC

TG Therapeutics Inc shares are higher in after-market hours, reflecting positive momentum following Monday's close, despite no specific news driving the movement.

22 авг. 2026 г., 00:02 UTC

Social Media

TG Therapeutics shares are higher in after-market trading amid positive investor sentiment and discussions of significant price targets of $150 following recent market pressures.

21 авг. 2026 г., 23:01 UTC

Social Media

TG Therapeutics Inc. is rising in after-market trading, fueled by positive investor sentiment and potential price targets between $150 and $200.

20 авг. 2026 г., 21:01 UTC

TG Therapeutics Inc shares are higher in after-market hours, despite earlier declines. No specific news was identified to explain the price movement.

19 авг. 2026 г., 19:27 UTC

TG Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday. The stock is trading above its 20-day moving average.

17 авг. 2026 г., 19:56 UTC

Social Media
News

TG Therapeutics reported Q2 2026 revenue of $240.34 million and raised its full-year outlook to $950 million, driving shares higher during Monday's trading.

14 авг. 2026 г., 21:01 UTC

TG Therapeutics Inc shares are lower in after-market trading amid broader market weakness. Disappointing U.S. retail sales data may be impacting investor sentiment.

13 авг. 2026 г., 20:02 UTC

Social Media

TG Therapeutics Inc shares declined during Thursday's session, influenced by social media sentiment and prior bearish commentary from Bank of America.

Сравнение c конкурентами

Изменение цены

TG Therapeutics Inc Прогноз

Целевая цена

By TipRanks

20.44% рост

Прогноз на 12 месяцев

Средняя 69.167 USD  20.44%

Максимум 86 USD

Минимум 21 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для TG Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

6 ratings

5

Покупка

0

Удержание

1

Продажа

Настроения

By Acuity

271 / 339Рейтинг в Здравоохранение

Новостные настроения

Свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.